| Filed On | Filing |
|---|---|
| 20 Oct 2026 |
8-K: Other Events
On October 16, 2026, the United States Court of Appeals for the Fifth Circuit (the “Fifth Circuit”) vacated the order of the U.S. District Court for the Western District of Texas (the “Texas District Court”) granting class certification ... |
| 01 Oct 2026 |
Form 4: Barry Richard, Director
Bought 206,813 shares ($186K) · Bought 100,000 shares ($92K) |
| 30 Sep 2026 |
Form 4: Barry Richard, Director
Bought 93,091 shares ($78.2K) |
| 22 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis C... |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 29 Jul 2026 | FORM 10-Q |
| 29 Jul 2026 | 8-K: Results of Operations and Financial Condition |
| 15 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders |
| 07 May 2026 | FORM 10-Q |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Apr 2026 | FORM ARS |
| 28 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $1.5M, down 91% · say-on-pay vote |
| 28 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 12 Mar 2026 | FORM 10-K |
| 12 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 10 Mar 2026 | 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure |
| 19 Feb 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 23 Dec 2025 | 8-K: Entry into a Material Definitive Agreement |
| 22 Dec 2025 | 8-K/A: Departure/Election of Directors or Officers; Compensation |
| 18 Dec 2025 | 8-K: Other Events |
Loading...
